cefotaxime

cefotaxime is a broad-spectrum antibiotic belonging to the third-generation cephalosporin class, widely utilized in clinical practice for its efficacy against a range of serious bacterial infections. It is particularly valued for its activity against Gram-negative organisms, including many Enterobacteriaceae, while retaining some potency against Gram-positive pathogens like Streptococcus pneumoniae. Developed by the Roussel-Uclaf pharmaceutical company, it is administered via intravenous or intramuscular routes and is often a first-line agent in hospital settings for conditions such as bacterial meningitis and sepsis.

Medical uses

Cefotaxime is indicated for the treatment of severe infections caused by susceptible organisms, including meningitis due to Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. It is a cornerstone therapy for community-acquired pneumonia and is also effective against gonorrhea caused by Neisseria gonorrhoeae, including penicillin-resistant strains. In surgical prophylaxis, particularly for colorectal surgery, it is often combined with metronidazole to cover anaerobic organisms. Its spectrum makes it useful for treating intra-abdominal infections, septic arthritis, and osteomyelitis, as recommended by guidelines from the Infectious Diseases Society of America.

Adverse effects

Common adverse effects are generally mild and include local reactions at the injection site, such as phlebitis, and gastrointestinal disturbances like diarrhea and nausea. As with other cephalosporins, there is a risk of *Clostridioides difficile*-associated diarrhea, which can progress to pseudomembranous colitis. Hypersensitivity reactions, ranging from skin rash to severe anaphylaxis, can occur, especially in patients with a history of penicillin allergy due to potential cross-reactivity. Rare but serious effects include neutropenia, thrombocytopenia, and transient elevations in liver function tests, such as those from the aspartate transaminase enzyme.

Pharmacology

Cefotaxime exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to essential penicillin-binding proteins. It demonstrates high stability against many beta-lactamase enzymes produced by Gram-negative bacteria, particularly those of the TEM-1 and SHV-1 types. The drug is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion; its half-life is approximately 1 hour in adults with normal renal function. A unique feature is its metabolism in the liver to an active metabolite, desacetylcefotaxime, which synergistically enhances antimicrobial activity, especially against organisms like Staphylococcus aureus.

History

Cefotaxime was synthesized in the late 1970s by scientists at the French pharmaceutical firm Roussel-Uclaf, marking a significant advancement in beta-lactam antibiotic development. Its introduction represented a major leap in overcoming antibiotic resistance, particularly among Enterobacteriaceae in hospital-acquired infections. The drug received approval from the U.S. Food and Drug Administration in the early 1980s and quickly became a critical agent in the global arsenal against sepsis and meningitis. The work on its structure-activity relationship contributed to the development of subsequent cephalosporins like ceftriaxone and cefepime.

Society and culture

Cefotaxime is available under various brand names worldwide, most notably as Claforan, and is included on the WHO Model List of Essential Medicines. Its cost and availability have been subjects of discussion within global health initiatives, such as those by the World Health Organization, aimed at combating antimicrobial resistance. The drug has been featured in numerous clinical trials, including studies coordinated by the National Institutes of Health, evaluating its role in neonatal sepsis in developing countries. Its use is guided by local antibiotic stewardship programs to preserve efficacy against emerging multidrug-resistant pathogens like ESBL-producing Escherichia coli.

Category:World Health Organization essential medicines Category:Cephalosporin antibiotics Category:Antibiotics